Dr. Molly Gallogly is a native of Philadelphia, PA. She earned her undergraduate degree at Grinnell College, where her education was supported by a Barry M. Goldwater Scholarship. She then matriculated into Case Western Reserve University’s Medical Scientist Training Program, where she earned both her medical degree and a PhD in pharmacology. During her graduate training, she earned an individual NIH F30 training grant for her work in redox signaling. Her PhD training culminated in four first-author publications as well as presentations at national and international meetings. Dr. Gallogly completed her internal medicine residency at University Hospitals Cleveland Medical Center and remained there for her hematology/oncology fellowship, where she served as chief fellow and pursued basic science research in signaling pathways in c-myc-driven hematologic malignancies, presenting her findings at the 2017 American Society of Hematology Annual Meeting. During her fellowship, Dr. Gallogly expanded her clinical focus beyond hematologic malignancies to include hematopoietic stem cell transplantation and its complications.
Dr. Gallogly's current area of clinical and research focus is graft vs. host disease, a life-threatening complication of allogeneic hematopoietic stem cell transplantation. In addition to attending on the malignant hematology and stem cell transplant clinical services, she has spearheaded a multidisciplinary graft vs. host disease outpatient clinic to provide focused care and offer clinical trial enrollment to affected patients.
Dr. Gallogly is a Paul Calabresi Scholar in the Case Comprehensive Cancer Center's Clinical Oncology Research Career Development Program (CORP). Her research project investigates the efficacy and mechanisms of two cellular therapies (extracorporeal photopheresis and mesenchymal stem cell infusion) for the treatment of steroid-refractory and high-risk graft vs. host disease.